According to the TCGA-LIHC data set, 31% of HCC patients harbored TP53 mutations (including missense, truncating, splicing, and inframe mutations), and they tended to have higher mitotic gene signature expression (Figure 3D). The gene discussed is TP53; the disease is hepatocellular carcinoma.